Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 60Etoposide 24Daunorubicin 24Filgrastim 19Idarubicin 16Mitoxantrone 13Busulfan 12tipifarnib 11Gemtuzumab 10fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 9Cyclophosphamide 9Flow Cytometry 8Clofarabine 8Azacitidine 8sargramostim 7Methotrexate 7Gene Expression Profiling 7Topotecan 6Cyclosporine 6valspodar 5alvocidib 5Radiotherapy 5Granulocyte Colony-Stimulating Factor 5aldesleukin 4Observation 4Bortezomib 4Arsenic Trioxide 4Antilymphocyte Serum 4Whole-Body Irradiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelomonocytic, Acute × Calicheamicins × Clear all
NCT00895934 2019-05-23

Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

National Cancer Institute (NCI)

Phase 1/2 Completed
52 enrolled 12 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡